JO3438B1 - Aryl- or heteroaryl-substituted benzene compounds - Google Patents

Aryl- or heteroaryl-substituted benzene compounds

Info

Publication number
JO3438B1
JO3438B1 JOP/2018/0104A JOP20180104A JO3438B1 JO 3438 B1 JO3438 B1 JO 3438B1 JO P20180104 A JOP20180104 A JO P20180104A JO 3438 B1 JO3438 B1 JO 3438B1
Authority
JO
Jordan
Prior art keywords
heteroaryl
aryl
substituted benzene
benzene compounds
compounds
Prior art date
Application number
JOP/2018/0104A
Other languages
Arabic (ar)
Inventor
K Knutson Sarah
Natalie Warholic
Syuji Shirotori
Christine Klaus
Richard Chesworth
Kenneth William Duncan
Kevin Wayne Kuntz
Masashi Seki
Heike Keilhack
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46045109&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3438(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of JOP20180104A1 publication Critical patent/JOP20180104A1/en
Application granted granted Critical
Publication of JO3438B1 publication Critical patent/JO3438B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof.
JOP/2018/0104A 2011-04-13 2011-04-13 Aryl- or heteroaryl-substituted benzene compounds JO3438B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161474821P 2011-04-13 2011-04-13
US201161499595P 2011-06-21 2011-06-21

Publications (2)

Publication Number Publication Date
JOP20180104A1 JOP20180104A1 (en) 2019-01-30
JO3438B1 true JO3438B1 (en) 2019-10-20

Family

ID=46045109

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2018/0104A JO3438B1 (en) 2011-04-13 2011-04-13 Aryl- or heteroaryl-substituted benzene compounds
JOP/2012/0087A JO3363B1 (en) 2011-04-13 2012-04-10 Aryl- or heteroaryl-substituted benzene compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2012/0087A JO3363B1 (en) 2011-04-13 2012-04-10 Aryl- or heteroaryl-substituted benzene compounds

Country Status (36)

Country Link
US (11) US8410088B2 (en)
EP (5) EP3943485B1 (en)
JP (6) JP5933686B2 (en)
KR (7) KR102032303B1 (en)
CN (2) CN104080769B (en)
AR (1) AR086008A1 (en)
AU (1) AU2012242595B2 (en)
BR (2) BR112013026324B1 (en)
CA (2) CA3086473A1 (en)
CL (1) CL2013002898A1 (en)
CY (3) CY1117986T1 (en)
DK (4) DK2697199T3 (en)
ES (3) ES2706951T3 (en)
FI (1) FI3943485T3 (en)
HK (1) HK1193804A1 (en)
HR (3) HRP20211297T8 (en)
HU (3) HUE042788T2 (en)
IL (3) IL228745A (en)
JO (2) JO3438B1 (en)
LT (4) LT3150580T (en)
ME (1) ME02500B (en)
MX (2) MX343685B (en)
MY (1) MY166171A (en)
NZ (3) NZ616298A (en)
PE (1) PE20140863A1 (en)
PH (1) PH12016502132A1 (en)
PL (4) PL2697199T3 (en)
PT (4) PT3943485T (en)
RS (3) RS55113B1 (en)
RU (1) RU2632193C2 (en)
SG (1) SG194447A1 (en)
SI (4) SI3486234T1 (en)
SM (1) SMT201600308B (en)
TW (1) TWI529162B (en)
WO (1) WO2012142504A1 (en)
ZA (1) ZA201307539B (en)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011160206A1 (en) 2010-06-23 2011-12-29 Morin Ryan D Biomarkers for non-hodgkin lymphomas and uses thereof
KR102511807B1 (en) 2010-09-10 2023-03-20 에피자임, 인코포레이티드 Inhibitors of human ezh2, and methods of use thereof
US9175331B2 (en) * 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
JO3438B1 (en) 2011-04-13 2019-10-20 Epizyme Inc Aryl- or heteroaryl-substituted benzene compounds
TW201733984A (en) 2011-04-13 2017-10-01 雅酶股份有限公司 Substituted benzene compounds
JP2014534178A (en) 2011-09-30 2014-12-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ Cancer treatment methods
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2014124418A1 (en) * 2013-02-11 2014-08-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CA2862289C (en) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
ES2718900T3 (en) * 2012-03-12 2019-07-05 Epizyme Inc Human EZH2 inhibitors and methods of use thereof
EP3628670B1 (en) 2012-04-13 2022-10-12 Epizyme, Inc. Salt form for ezh2 inhibition
KR20200062386A (en) * 2012-04-13 2020-06-03 에피자임, 인코포레이티드 Combination therapy for treating cancer
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
CA2884848C (en) * 2012-09-28 2017-08-22 Pfizer Inc. Benzamide and heterobenzamide compounds
RU2658919C2 (en) 2012-10-15 2018-06-26 Эпизайм, Инк. Substituted benzene compounds
EP3659606A1 (en) * 2012-10-15 2020-06-03 Epizyme, Inc. Methods of treating cancer
KR20150095779A (en) 2012-12-13 2015-08-21 글락소스미스클라인 엘엘씨 Enhancer of zeste homolog 2 inhibitors
EP2934531A4 (en) * 2012-12-19 2016-06-15 Glaxosmithkline Llc Combination
AU2013361079B2 (en) 2012-12-21 2018-07-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
EP2935214B1 (en) * 2012-12-21 2019-02-20 Epizyme, Inc. 1,4-pyridone compounds
UA111305C2 (en) 2012-12-21 2016-04-11 Пфайзер Інк. Condensed with lactams of aryl and heteroaryl
WO2014153100A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EA030481B1 (en) 2013-03-14 2018-08-31 Эпизим, Инк. Arginine methyltransferase inhibitors and uses thereof
CA2903264A1 (en) 2013-03-14 2014-11-06 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153235A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
CA2905070A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
WO2014153214A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
EP2970133B1 (en) 2013-03-14 2018-10-24 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
EP2970181B1 (en) 2013-03-14 2017-06-07 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153090A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives asprmt1 inhibitors and uses thereof
US9243001B2 (en) 2013-03-15 2016-01-26 Epizyme, Inc. Substituted benzene compounds
US20160031907A1 (en) 2013-03-15 2016-02-04 Epizyme, Inc. Substituted Benzene Compounds
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
MX2015015144A (en) 2013-04-30 2016-02-18 Glaxosmithkline Ip No 2 Ltd Enhancer of zeste homolog 2 inhibitors.
BR112015030515A2 (en) * 2013-06-06 2017-07-25 Glaxosmithkline Ip No 2 Ltd zeste homolog 2 inhibitor enhancers
RU2016104044A (en) 2013-07-10 2017-08-15 Глэксосмитклайн Интеллекчуал Проперти (Nо.2) Лимитед ZESTE Homolog Amplifier Inhibitors 2
EP3022195A2 (en) 2013-07-19 2016-05-25 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP3022184B1 (en) * 2013-07-19 2017-09-27 Epizyme, Inc. Substituted benzene compounds
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
SG10201901977XA (en) * 2013-10-16 2019-04-29 Epizyme Inc Hydrochloride salt form for ezh2 inhibition
US9738630B2 (en) 2013-11-19 2017-08-22 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
US9822103B2 (en) 2013-11-22 2017-11-21 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
KR102473113B1 (en) 2013-12-06 2022-12-01 에피자임, 인코포레이티드 Combination therapy for treating cancer
CN105037360B (en) * 2014-04-28 2016-08-17 四川大学 Pyridione derivatives and its production and use
KR102497728B1 (en) 2014-06-17 2023-02-09 에피자임, 인코포레이티드 Ezh2 inhibitors for treating lymphoma
AU2015275826B2 (en) 2014-06-17 2019-05-16 Pfizer Inc. Substituted dihydroisoquinolinone compounds
EP3160940A4 (en) 2014-06-25 2018-05-02 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
MX2017004969A (en) 2014-10-16 2017-07-19 Epizyme Inc Method for treating cancer.
CN107148419A (en) * 2014-10-28 2017-09-08 葛兰素史密斯克莱知识产权（第2 号）有限公司 The inhibitor of ZESTE enhancers homologue 2
WO2016073956A1 (en) 2014-11-06 2016-05-12 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
PL3220916T3 (en) 2014-11-17 2023-08-14 Epizyme, Inc. Method for treating cancer with n-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl) amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide
AR102767A1 (en) 2014-12-05 2017-03-22 Lilly Co Eli EZH2 INHIBITORS
SG10201902664RA (en) 2015-04-20 2019-04-29 Epizyme Inc Combination therapy for treating cancer
EP3307713A4 (en) 2015-06-10 2019-01-23 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
UY36758A (en) * 2015-06-30 2016-12-30 Glaxosmithkline Ip No 2 Ltd INHIBITORS OF THE ZESTE 2 HOMOLOGIST POTENTIATOR
EP3341080A4 (en) 2015-08-24 2019-03-20 Epizyme Inc Method for treating cancer
TW201718598A (en) 2015-08-27 2017-06-01 美國禮來大藥廠 Inhibitors of EZH2
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
CN108699046A (en) * 2015-10-06 2018-10-23 Epizyme股份有限公司 With the method for EZH2 inhibitor for treating medulloblastomas
WO2017079757A1 (en) * 2015-11-06 2017-05-11 Epizyme, Inc. Pediatric dosing for treatment of cancer with an ezh2 inhibitor
US10759787B2 (en) 2015-11-19 2020-09-01 Jiangsu Hengrui Medicine Co., Ltd. Benzofuran derivative, preparation method thereof and use thereof in medicine
CN105440023A (en) * 2015-12-10 2016-03-30 江苏理工学院 Synthetic method of EPZ-6438
TW202246215A (en) 2015-12-18 2022-12-01 美商亞德利克斯公司 Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists
US11951108B2 (en) * 2016-01-29 2024-04-09 Epizyme, Inc. Combination therapy for treating cancer
EP3429571A1 (en) 2016-03-15 2019-01-23 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for use in the treatment of solid tumors
WO2017174023A1 (en) * 2016-04-08 2017-10-12 南京明德新药研发股份有限公司 Biphenyl compound serving as ezh2 inhibitor
US10633371B2 (en) * 2016-04-22 2020-04-28 Dana-Farber Cancer Institute, Inc. EZH2 inhibitors and uses thereof
WO2017192290A1 (en) 2016-05-04 2017-11-09 The Wistar Institute Of Anatomy And Biology Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and platinum-based antineoplastic drugs
AU2017260854B2 (en) 2016-05-05 2020-01-30 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of Zeste Homolog 2 inhibitors
WO2017210395A1 (en) * 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
MA45406A (en) 2016-06-17 2019-04-24 Epizyme Inc EZH2 INHIBITORS TO TREAT CANCER
CN109843870A (en) 2016-10-19 2019-06-04 星座制药公司 The synthesis of EZH2 inhibitor
AU2017367768A1 (en) 2016-12-02 2019-07-18 Epizyme, Inc. Combination therapy for treating cancer
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
CN108314677B (en) 2017-01-17 2020-06-30 安徽中科拓苒药物科学研究有限公司 EZH2 inhibitor and application thereof
KR20190105602A (en) 2017-01-19 2019-09-17 다이이찌 산쿄 가부시키가이샤 Pharmaceutical composition for use in treating HTLV-1 related myelopathy
CN110191879A (en) * 2017-01-25 2019-08-30 恩瑞生物医药科技（上海）有限公司 A kind of histone methyltransferase EZH2 inhibitor, preparation method and its medical usage
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
US11672800B2 (en) * 2017-04-21 2023-06-13 Epizyme, Inc. Combination therapies with EHMT2 inhibitors
WO2018210302A1 (en) 2017-05-18 2018-11-22 江苏恒瑞医药股份有限公司 Crystal of benzofuran derivative free base and preparation method
EP3630080A4 (en) 2017-06-02 2021-03-10 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
US20230201212A1 (en) 2017-06-13 2023-06-29 Epizyme, Inc. Inhibitors of ezh2 and methods of use thereof
WO2019050924A1 (en) * 2017-09-05 2019-03-14 Epizyme, Inc. Combination therapy for treating cancer
US11529344B2 (en) 2017-11-14 2022-12-20 Pfizer Inc. EZH2 inhibitor combination therapies
ES2923290T3 (en) 2018-01-31 2022-09-26 Mirati Therapeutics Inc PRC2 inhibitors
CN108640842B (en) * 2018-04-04 2021-06-04 大连九信精细化工有限公司 Synthetic method of 2-bromo-5-fluoronitrobenzene
EP3802627A4 (en) 2018-06-07 2022-03-09 Merck Sharp & Dohme Corp. Processes for the preparation of sugammadex
JP2021531340A (en) 2018-07-09 2021-11-18 フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles Inhibition of the PRC2 subunit to treat eye disorders
KR20210040077A (en) * 2018-07-27 2021-04-12 쑤저우 시노벤트 파마슈티칼즈 씨오., 엘티디. Polysubstituted benzene compound and its preparation method
KR20200101219A (en) 2019-02-19 2020-08-27 한미약품 주식회사 Novel heterotricyclic derivatives and use thereof
US20220098178A1 (en) * 2019-03-25 2022-03-31 Shanghai Synergy Pharmaceutical Sciences Co., Ltd. Preparation Method for Amide Compound and Application Thereof in Field of Medicine
WO2021035194A1 (en) 2019-08-22 2021-02-25 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
CN115551842B (en) * 2020-06-08 2024-04-23 南京明德新药研发有限公司 Biphenyl compounds
CA3195479A1 (en) * 2020-10-13 2022-04-21 Xufan WANG Crystal form of multi-substituted benzene ring compound maleate, and preparation method therefor and use thereof
CN114907299A (en) * 2021-02-08 2022-08-16 上海医药工业研究院 Novel salt form of tarezostat key intermediate, preparation method thereof and intermediate thereof
CN114907300B (en) * 2021-02-08 2024-05-28 上海医药工业研究院 Preparation method of tazistat key intermediate and intermediate thereof
CN113292489B (en) * 2021-06-16 2022-08-30 泓博智源(开原)药业有限公司 Preparation method of dichlorodialkyl nicotinonitrile
CN113527275A (en) * 2021-07-20 2021-10-22 成都师范学院 SKLB1039 compound and preparation method and application thereof
CN113582863B (en) * 2021-08-19 2023-05-26 沈阳农业大学 Aminoethyl biphenyl compound and preparation method and application thereof
KR20230081459A (en) 2021-11-30 2023-06-07 엘젠테라퓨틱스 주식회사 Novel 3-pyridine and 4-phenylpyridine derivatives substituted with heterocyclics and uses thereof
WO2023111810A1 (en) 2021-12-14 2023-06-22 Pfizer Inc. Combination therapies and uses for treating cancer
WO2023209591A1 (en) 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
WO2023244917A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders
WO2023244918A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
CN115197202B (en) * 2022-07-15 2024-01-26 四川大学 EZH2 covalent inhibitor and preparation method and application thereof

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPH0733729A (en) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Production of n-cyano-n'-substituted-arylcarboxyimidamide compound
ATE180468T1 (en) 1993-12-27 1999-06-15 Eisai Co Ltd ANTHRANILIC ACID DERIVATIVES
DE19516776A1 (en) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin regulatory genes
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
JP3906935B2 (en) 1995-12-18 2007-04-18 杏林製薬株式会社 N-substituted dioxothiazolidylbenzamide derivative and process for producing the same
BR9914207A (en) 1998-09-30 2001-07-03 Procter & Gamble 2-substituted keto-amides
UA71587C2 (en) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Anthranilic acid amides and use thereof as medicaments
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
ES2330719T3 (en) 2000-12-28 2009-12-15 SHIONOGI & CO., LTD. DERIVATIVES OF 2-PIRIDONE WITH AFFINITY FOR THE CANNABINOID RECEIVER TYPE 2.
US20040102455A1 (en) * 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
WO2003059884A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
DE60329981D1 (en) 2002-02-19 2009-12-24 Shionogi & Co antipruritics
TW200306155A (en) 2002-03-19 2003-11-16 Du Pont Benzamides and advantageous compositions thereof for use as fungicides
CA2510051C (en) 2002-12-27 2016-07-05 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort
CN103265477B (en) * 2003-02-26 2017-01-11 苏根公司 Aminoheteroaryl compounds as protein kinase inhibitors
US7405295B2 (en) * 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
US7560467B2 (en) 2003-06-19 2009-07-14 Smithkline Beecham Corporation Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors
KR101139557B1 (en) * 2003-07-23 2012-04-30 바이엘 파마슈티칼스 코포레이션 Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
JP4338734B2 (en) 2003-08-26 2009-10-07 メルク エイチディーエーシー リサーチ エルエルシー Cancer treatment with HDAC inhibitors
US20050059682A1 (en) 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
BRPI0508579A (en) 2004-03-11 2007-08-14 Actelion Pharmaceuticals Ltd compound, pharmaceutical composition, and use of a compound
CN1286973C (en) 2004-04-12 2006-11-29 上海第二医科大学附属瑞金医院 Histone methyl transferase and its preparing method
DE602005017781D1 (en) 2004-06-01 2009-12-31 Univ North Carolina RECONSTITUTED HISTON METHYLTRANSFERASE COMPLEX AND METHOD FOR IDENTIFYING MODULATORS THEREFOR
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Substituted Amid derivatives & methods of use
EP1891434B1 (en) 2005-06-02 2011-01-05 The University of North Carolina at Chapel Hill Purification, characterization and reconstitution of a ubiquitin e3 ligase
FR2889526B1 (en) 2005-08-04 2012-02-17 Aventis Pharma Sa SUBSTITUTED 7-AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PRODUCTION AND USE
ES2416336T3 (en) 2005-10-19 2013-07-31 Grünenthal GmbH New vanilloid receptor ligands and their use for the production of medicines
CA2626402C (en) 2005-10-21 2011-02-15 Merck & Co., Inc. Potassium channel inhibitors
EP1941060B1 (en) 2005-10-28 2012-02-29 The University of North Carolina At Chapel Hill Protein demethylases comprising a jmjc domain
CN101365806B (en) 2005-12-01 2016-11-16 医学预后研究所 For identifying method and apparatus and the purposes of prediction curative effect thereof of the biomarker of therapeutic response
KR20080080173A (en) 2005-12-14 2008-09-02 브리스톨-마이어스 스큅 컴퍼니 Six-membered heterocycles useful as serine protease inhibitors
EP2730661A1 (en) 2006-01-20 2014-05-14 The University of North Carolina at Chapel Hill Diagnostic and therapeutic targets for leukemia
JP2009537521A (en) 2006-05-15 2009-10-29 アイアールエム・リミテッド・ライアビリティ・カンパニー Terephthalamate compounds and compositions and their use as HIV integrase inhibitors
US20070287706A1 (en) 2006-05-18 2007-12-13 Dickson John K Jr Certain substituted quinolones, compositions, and uses thereof
US8022246B2 (en) 2006-10-10 2011-09-20 The Burnham Institute For Medical Research Neuroprotective compositions and methods
US8314087B2 (en) 2007-02-16 2012-11-20 Amgen Inc. Nitrogen-containing heterocyclyl ketones and methods of use
WO2008104077A1 (en) 2007-02-28 2008-09-04 Methylgene Inc. Small molecule inhibitors of protein arginine methyltransferases (prmts)
WO2008109534A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting ezh2 gene expression and uses thereof
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
DE102007017884A1 (en) 2007-04-13 2008-10-16 Grünethal GmbH Novel vanilloid receptor ligands and their use in the preparation of medicines
US20090012031A1 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan EZH2 Cancer Markers
US8110572B2 (en) 2007-07-16 2012-02-07 Abbott Laboratories Inhibitors of protein kinases
CA2703909A1 (en) * 2007-10-31 2009-05-07 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
US8198279B2 (en) 2007-12-19 2012-06-12 Institute Of Cancer Research: Royal Cancer Hospital (The) Pyrido[2,3-b]pyrazin-8-substituted compounds and their use
US8558000B2 (en) * 2008-01-23 2013-10-15 Bristol-Myers Squibb Company 4-pyridinone compounds and their use for cancer
WO2009124137A2 (en) 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Method of suppressing gene transcription through histone lysine methylation
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
UY31982A (en) * 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVATIVES OF 1,2-DIHYDROPIRIDIN-3-CARBOXAMIDS N-SUBSTITUTED
JP5548197B2 (en) 2008-08-08 2014-07-16 ニューヨーク ブラッド センター， インコーポレイテッド Small molecule inhibitors of retrovirus assembly and maturation
FR2934995B1 (en) 2008-08-14 2010-08-27 Sanofi Aventis POLYSUBSTITUTED AZETIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
US20120208809A1 (en) * 2009-03-24 2012-08-16 Sanofi 9h-pyrrolo[2,3-b: 5,4-c'] dipyridine azacarboline derivatives, preparation thereof, and therapeutic use thereof
US20120065247A1 (en) 2009-03-27 2012-03-15 Discoverybiomed, Inc. Modulating ires-mediated translation
WO2011011366A2 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
EP2521558A4 (en) 2009-12-30 2013-07-03 Avon Prod Inc Topical lightening composition and uses thereof
WO2012005805A1 (en) * 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
WO2011140325A1 (en) * 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
NZ603454A (en) * 2010-05-07 2014-06-27 Glaxosmithkline Llc Indoles useful for treating cellular proliferation diseases such as cancer
WO2011160206A1 (en) 2010-06-23 2011-12-29 Morin Ryan D Biomarkers for non-hodgkin lymphomas and uses thereof
KR102511807B1 (en) 2010-09-10 2023-03-20 에피자임, 인코포레이티드 Inhibitors of human ezh2, and methods of use thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US8765792B2 (en) 2010-12-01 2014-07-01 Glaxosmithkline Llc Indoles
US9145438B2 (en) 2010-12-03 2015-09-29 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
EP2681216B1 (en) 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (en) 2011-04-13 2019-10-20 Epizyme Inc Aryl- or heteroaryl-substituted benzene compounds
TW201733984A (en) * 2011-04-13 2017-10-01 雅酶股份有限公司 Substituted benzene compounds
JP2014534178A (en) 2011-09-30 2014-12-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ Cancer treatment methods
ES2718900T3 (en) * 2012-03-12 2019-07-05 Epizyme Inc Human EZH2 inhibitors and methods of use thereof
KR20200062386A (en) 2012-04-13 2020-06-03 에피자임, 인코포레이티드 Combination therapy for treating cancer
EP3628670B1 (en) 2012-04-13 2022-10-12 Epizyme, Inc. Salt form for ezh2 inhibition
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
EP3659606A1 (en) 2012-10-15 2020-06-03 Epizyme, Inc. Methods of treating cancer
RU2658919C2 (en) 2012-10-15 2018-06-26 Эпизайм, Инк. Substituted benzene compounds

Also Published As

Publication number Publication date
JP5933686B2 (en) 2016-06-15
CA2832843A1 (en) 2012-10-18
US9522152B2 (en) 2016-12-20
RS62279B1 (en) 2021-09-30
ES2886099T3 (en) 2021-12-16
EP4360712A2 (en) 2024-05-01
US20120264734A1 (en) 2012-10-18
RS58226B1 (en) 2019-03-29
PT2697199T (en) 2016-09-05
EP3943485A1 (en) 2022-01-26
EP3486234A1 (en) 2019-05-22
JP2023011933A (en) 2023-01-24
US10420775B2 (en) 2019-09-24
CL2013002898A1 (en) 2014-08-22
AU2012242595B2 (en) 2014-05-15
US8765732B2 (en) 2014-07-01
IL228745A (en) 2016-12-29
KR102566864B1 (en) 2023-08-11
LT3150580T (en) 2019-02-11
BR112013026324A8 (en) 2018-01-30
JP2019014732A (en) 2019-01-31
KR102154946B1 (en) 2020-09-10
US20210379076A1 (en) 2021-12-09
AU2012242595A1 (en) 2013-05-02
EP2697199A1 (en) 2014-02-19
MY166171A (en) 2018-06-07
EP2697199B1 (en) 2016-06-08
WO2012142504A1 (en) 2012-10-18
HRP20190074T1 (en) 2019-03-08
PL3486234T3 (en) 2021-11-29
RS55113B1 (en) 2016-12-30
RU2017132054A3 (en) 2021-05-14
US9090562B2 (en) 2015-07-28
US9855275B2 (en) 2018-01-02
CY1121120T1 (en) 2019-12-11
PL2697199T3 (en) 2016-12-30
HUE056552T2 (en) 2022-02-28
SI3486234T1 (en) 2021-12-31
FI3943485T3 (en) 2024-01-29
PL3150580T3 (en) 2019-04-30
SG194447A1 (en) 2013-12-30
LT2697199T (en) 2016-09-26
KR20190025055A (en) 2019-03-08
US20160022693A1 (en) 2016-01-28
CA3086473A1 (en) 2012-10-18
KR20230134128A (en) 2023-09-20
US20200155562A1 (en) 2020-05-21
SI3150580T1 (en) 2019-03-29
KR20140029442A (en) 2014-03-10
IL249273B (en) 2019-05-30
JP2018104450A (en) 2018-07-05
IL228745A0 (en) 2013-12-31
CY1124617T1 (en) 2022-07-22
IL266418A (en) 2019-06-30
US11052093B2 (en) 2021-07-06
SMT201600308B (en) 2016-11-10
NZ717119A (en) 2017-10-27
TWI529162B (en) 2016-04-11
DK3150580T3 (en) 2019-02-04
US20150353494A1 (en) 2015-12-10
ES2706951T3 (en) 2019-04-01
HRP20211297T1 (en) 2021-12-10
PT3943485T (en) 2024-03-06
NZ616298A (en) 2016-03-31
PL3943485T3 (en) 2024-05-20
BR122020006541B1 (en) 2022-05-10
EP3943485B1 (en) 2023-12-27
KR20180120275A (en) 2018-11-05
BR112013026324A2 (en) 2016-10-11
KR101914321B1 (en) 2018-11-02
EP3150580A1 (en) 2017-04-05
LT3943485T (en) 2024-02-12
HK1193804A1 (en) 2014-10-03
US20130123234A1 (en) 2013-05-16
HRP20211297T8 (en) 2022-02-18
US8410088B2 (en) 2013-04-02
ES2589555T3 (en) 2016-11-15
MX2013011921A (en) 2014-03-27
KR102308488B1 (en) 2021-10-06
PH12016502132A1 (en) 2017-05-22
CN104080769A (en) 2014-10-01
KR20210118968A (en) 2021-10-01
KR101955871B1 (en) 2019-03-08
CN107311921A (en) 2017-11-03
MX2020012695A (en) 2021-04-12
PT3150580T (en) 2019-01-28
NZ734744A (en) 2019-03-29
RU2632193C2 (en) 2017-10-03
SI2697199T1 (en) 2016-10-28
CY1117986T1 (en) 2017-05-17
EP3150580B1 (en) 2018-10-17
US20170252349A1 (en) 2017-09-07
TW201302704A (en) 2013-01-16
CN104080769B (en) 2017-06-20
HUE028837T2 (en) 2017-01-30
ME02500B (en) 2017-02-20
CA2832843C (en) 2020-09-29
JO3363B1 (en) 2019-03-13
DK3486234T3 (en) 2021-08-16
JP2016147886A (en) 2016-08-18
DK2697199T3 (en) 2016-09-12
BR112013026324B1 (en) 2020-12-08
CN107311921B (en) 2021-02-12
JOP20180104A1 (en) 2019-01-30
HUE042788T2 (en) 2019-07-29
KR20190121386A (en) 2019-10-25
ZA201307539B (en) 2014-06-25
PE20140863A1 (en) 2014-07-19
KR20200105543A (en) 2020-09-07
JP2014516931A (en) 2014-07-17
SI3943485T1 (en) 2024-04-30
DK3943485T3 (en) 2024-01-22
MX343685B (en) 2016-11-17
EP3486234B1 (en) 2021-06-02
US20170119780A1 (en) 2017-05-04
US20190192526A1 (en) 2019-06-27
IL249273A0 (en) 2017-01-31
US20140288041A1 (en) 2014-09-25
RU2017132054A (en) 2019-02-06
LT3486234T (en) 2021-09-10
JP6778226B2 (en) 2020-10-28
KR102032303B1 (en) 2019-10-15
US20180318309A1 (en) 2018-11-08
US10155002B2 (en) 2018-12-18
PT3486234T (en) 2021-09-07
RU2013150345A (en) 2015-05-20
JP2021042243A (en) 2021-03-18
HRP20161115T1 (en) 2016-11-18
AR086008A1 (en) 2013-11-13
US9549931B2 (en) 2017-01-24

Similar Documents

Publication Publication Date Title
PH12016502132A1 (en) Aryl-or heteroaryl-substituted benzene compounds
MX344530B (en) Substituted benzene compounds.
PH12015500825A1 (en) Substituted benzene compounds
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
MX2020010535A (en) Methods of treating cancer.
TN2015000278A1 (en) Autotaxin inhibitors
IN2014MN00986A (en)
IN2014MN00948A (en)
UA109464C2 (en) Spiro-oxindoles as mdm2 antagonists
IN2012MN02591A (en)
MX349004B (en) New compounds.
MX346375B (en) Spiro-oxindole mdm2 antagonists.
IN2014MN00988A (en)
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
MX342924B (en) Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases.
IN2015DN02109A (en)
UA110969C2 (en) Aryl- or heteroaryl substituted benzene compounds and pharmaceutical compositions based thereon
TN2013000202A1 (en) Spiro-oxindole mdm2 antagonists
MX2012007471A (en) Substituted pyrrolo-aminopyrimidine compounds.